For the most vulnerable patients, the volume required for an analysis is a critical medical, operational and technological factor.
Blood collection is a routine procedure, but its impact varies significantly between patients. For a newborn, a premature infant or a particularly vulnerable patient, the amount of blood available, the frequency of sampling and the repetition of tests must be assessed carefully. In these situations, the volume required for an analysis is not merely a technical parameter.
Constraints increase when several analyses are required or when the patient’s condition demands repeated measurements. Each sample involves time, equipment, trained professionals and an organisation adapted to the clinical context. It may also require several tubes or processing stages, depending on the requested tests. Reducing the required volume while maintaining analytical quality may therefore create practical operational value. Discover our Medical Applications to learn more about these clinical use cases.
Miniaturisation makes it possible to consider measuring several parameters from a single microsample. Through multiplexing, a platform may quantify several biomarkers or medications without increasing sample volumes proportionally. This capability is particularly relevant in environments where every collected volume matters. It remains dependent on assay reliability, biomarker selection and protocol validation for each patient population.
FoRe technology is designed to operate using less than 50 µL of blood and to measure several parameters simultaneously. Preciphos identifies paediatrics, neonatology and critical care among the priority environments being considered. Beyond the medical relevance, this capability may improve workflow efficiency, reduce selected resource requirements and facilitate the development of targeted assay panels. Discover how Hospitals & Decision Makers can benefit from integrating this approach into their clinical workflows. For healthcare institutions and financial partners, it demonstrates how a precise clinical constraint can become the starting point for differentiated technology and a high-value market opportunity.